EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025
Rhea-AI Summary
EDAP TMS (NASDAQ:EDAP), the global leader in robotic energy-based therapies, will release its Q2 2025 financial results on Thursday, August 28th, 2025, before market open.
The company will host a conference call and webcast at 8:30 AM EDT on the same day, featuring CEO Ryan Rhodes, CFO Ken Mobeck, and CAO François Dietsch. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using passcode EDAP, or through the company's webcast platform.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EDAP gained 3.20%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.5% during that session. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $53M at that time.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT
AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the markets open on Thursday, August 28th, 2025.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
Date: Thursday, August 28th
Time: 8:30 am EDT
Domestic: 1-800-274-8461
International: 1-203-518-9814
Passcode: EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1726716&tp_key=220919ac3d
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
When will EDAP (NASDAQ:EDAP) report Q2 2025 earnings?
How can investors join EDAP's Q2 2025 earnings call?
Who will present during EDAP's Q2 2025 earnings call?
What time is EDAP's Q2 2025 earnings conference call?
